98%
921
2 minutes
20
Background: Vertigo or dizziness (VDS) are common reasons for emergency department (ED) visits and pose significant challenges in the early identification of acute ischemic stroke (AIS). The TriAGe + score was developed to predict AIS in patients presenting with VDS without relying on neuroimaging; however, its diagnostic accuracy compared with ABCD-based scores remains uncertain. This study aims to evaluate the efficacy of the TriAGe + score in distinguishing central ischemic causes from peripheral etiologies in patients with VDS and to compare its predictive accuracy for AIS, including posterior circulation infarctions (PCIs), with that of the ABCD2, ABCD3, and ABCD3-I scores.
Methods: This retrospective cohort study evaluated 1,138 patients who presented to a tertiary ED with VDS complaints between January 2023 and July 2024. After applying the exclusion criteria, 886 patients were included. All patients underwent diffusion-weighted magnetic resonance imaging within 72 h for diagnostic confirmation. On the basis of the imaging results, 210 patients were diagnosed with AIS, while 676 patients without findings consistent with AIS were considered the control group. The predictive performance of the TriAGe + and ABCD scores was evaluated in both groups via logistic regression and receiver operating characteristic (ROC) analyses.
Results: PCIs accounted for 74.3% of all AIS cases. The TriAGe + score demonstrated greater diagnostic accuracy than did the ABCD scores in the ROC analysis among all patients (AUC = 0.979; 95% confidence interval [CI]: 0.967-0.987). For the diagnosis of AIS in all patients, the TriAGe + score had a cutoff value of > 7, with a sensitivity of 91% and a specificity of 91.3%. In patients without focal weakness or sensory loss, the TriAGe + score remained a strong predictor of AIS, with a cutoff value of 5, yielding a sensitivity of 97.5% and a specificity of 80.9% (AUC = 0.950; 95% CI: 0.932-0.964).
Conclusion: The TriAGe + score is useful in the diagnosis of AIS in patients presenting to the ED with VDS complaints. It outperforms ABCD scores in sensitivity and specificity, particularly in cases without focal neurological deficits. Implementing the TriAGE + score may optimize neuroimaging use, reduce healthcare costs, and improve ED efficiency by assisting clinicians in prioritizing high-risk patients.
Clinical Trial Number: Not applicable.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12261693 | PMC |
http://dx.doi.org/10.1186/s12873-025-01284-y | DOI Listing |
JCI Insight
September 2025
Edinburgh Medical School: Biomedical Sciences & Euan MacDonald Centre for M, University of Edinburgh, Edinburgh, United Kingdom.
Spinal muscular atrophy (SMA) is a neuromuscular disease caused by low levels of SMN protein. Several therapeutic approaches boosting SMN are approved for human patients, delivering remarkable improvements in lifespan and symptoms. However, emerging phenotypes, including neurodevelopmental comorbidities, are being reported in some treated SMA patients, indicative of alterations in brain development.
View Article and Find Full Text PDFJCI Insight
September 2025
Division of Nephrology, Boston University Chobanian & Avedisian School of Medicine, Boston, United States of America.
Background: Active vitamin D metabolites, including 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D), have potent immunomodulatory effects that attenuate acute kidney injury (AKI) in animal models.
Methods: We conducted a phase 2, randomized, double-blind, multiple-dose, 3-arm clinical trial comparing oral calcifediol (25D), calcitriol (1,25D), and placebo among 150 critically ill adult patients at high-risk of moderate-to-severe AKI. The primary endpoint was a hierarchical composite of death, kidney replacement therapy (KRT), and kidney injury (baseline-adjusted mean change in serum creatinine), each assessed within 7 days following enrollment using a rank-based procedure.
Clin J Am Soc Nephrol
September 2025
University College London Great Ormond Street Hospital for Children and Institute of Child Health, London, UK.
Background: Experience with icodextrin use in children on long-term peritoneal dialysis is limited. We describe international icodextrin prescription practices and their impact on clinical outcomes: ultrafiltration, blood pressure control, residual kidney function (RKF), technique and patient survival.
Methods: We included patients under 21 years enrolled in the International Pediatric Peritoneal Dialysis Network (IPPN) between 2007 and 2024, on automated PD with a daytime dwell.
Kidney360
September 2025
Department of Pediatrics, Division of Pediatric Nephrology, Baylor College of Medicine, Houston, TX, United States.
Background: Dialysis in neonates with ESKD is often associated with multiple comorbidities and the need for more intensified dialysis regimens. With recent advances in prenatal interventions and infant specific KRT, survival of neonates with ESKD has improved over the last decade. Little is known however about the impact on the health care system of improved survival in this population.
View Article and Find Full Text PDFClin J Am Soc Nephrol
September 2025
Kidney Division, Peking University First Hospital, Peking University Institute of Nephrology; Key Laboratory of Kidney Disease, Ministry of Health of China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, China.
Background: The Therapeutic Effects of Steroids in IgA Nephropathy Global (TESTING) trial demonstrated that glucocorticoid therapy reduced proteinuria and improved kidney outcomes in patients with Immunoglobulin A Nephropathy (IgAN). Galactose-deficient IgA1 (Gd-IgA1) plays a central role in IgAN pathogenesis by promoting immune complex formation. However, the effects of glucocorticoid on pathogenic IgA levels remain unclear.
View Article and Find Full Text PDF